DelNS1-2019-nCoV-RBD-OPT
From Wikipedia, the free encyclopedia
Vaccine against COVID-19
Pharmaceutical compound
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | Pneucolin |
| Other names | DelNS1-nCoV-RBD LAIV[1] |
| Routes of administration | Intranasal |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.[3][4][5] It is administered as a single dose intranasal spray.[6]
On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.[7]
- ↑ "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
- ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ↑ "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Archived from the original on 14 September 2021. Retrieved 10 July 2021.
- ↑ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
- ↑ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
- ↑ Mi H, Chen Q, Lin H, He T, Zhang R, Ren S, et al. (January 2024). "Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study". eClinicalMedicine. 67 102374. doi:10.1016/j.eclinm.2023.102374. PMC 10758709. PMID 38169940.
- ↑ "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" [Notice on the implementation plan for the second dose of new coronavirus vaccine booster vaccination] (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.
Scholia has a profile for DelNS1-2019-nCoV-RBD-OPT (Q106522065).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by adding missing information. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by adding missing information. |